Latest Commercialisation Strategy News

Tartana Minerals has kicked off an ambitious drilling program at its Tartana Copper Project aiming to more than double its contained copper resource beyond the existing open pit. Early drilling progress and operational upgrades signal a push toward expanding production and resource depth.

1414 Degrees has formed an Aerospace, Drone & Defence Advisory Board featuring six veterans from top defence and aerospace firms to accelerate the rollout of its SiNTL silicon anode battery technology targeting drones and adjacent markets.

Terragen Holdings secures a landmark supply agreement for its probiotic and biostimulant products with Ravensworth Feedlot, alongside a $2.8 million funded trial at Mort & Co’s Grassdale feedlot to validate its probiotic’s impact on cattle performance.

NoviqTech's Coralia has kicked off a comprehensive trial converting invasive Chinese Apple trees into biochar at its Great Barrier Reef project, aiming to validate carbon removal methods and support institutional partnerships.

Cleo Diagnostics has laid out a clear U.S. reimbursement pathway for its ovarian cancer test, leveraging an existing CPT code to enable early market entry and data collection ahead of FDA clearance.

Bayan Mining and US Critical Materials have signed a non-binding MoU to develop rare-earth processing technologies licensed from the Colorado School of Mines, targeting high-grade mineralisation at the Sheep Creek Project in Montana. The collaboration aims to support a US-based rare earth supply chain with potential strategic investment on the horizon.

Nexsen has secured a strategic partnership with GHK Hospital Limited in Hong Kong, marking a significant step in validating and commercialising its rapid point-of-care diagnostics across North Asia.

Adisyn has appointed Tamir Zimber, a former Israeli Air Defence Colonel and current senior IAI executive, to its new Advisory Board, aiming to accelerate commercialisation of its graphene-based radar absorption technology.

Forte Energy has rapidly expanded its oil and gas exploration portfolio in Alaska’s National Petroleum Reserve, acquiring over 156,000 acres including the billion-barrel Harrier Prospect and adjacent leases to Umiat Oil Field, while securing significant cost savings through lease fee suspensions.

Rhythm Biosciences marked a pivotal shift from development to commercial diagnostics in Q3 FY26, recording its first ColoSTAT® clinical sale and initiating NHS England evaluation while expanding geneType™ partnerships across Asia and Australia.

Orthocell has initiated commercial sales of its Remplir nerve repair device in Canada, leveraging a distributor-led model to penetrate a US$75 million market and setting the stage for broader North American expansion.

xReality Group delivered a standout Q3 FY26 with a 62% jump in cash receipts and a new Mixed Reality sale to the US Department of Defense, underpinning its growing Operator XR platform.